– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for ...

Antiviral improved overall patient-reported measures of both upper, lower respiratory symptoms, shortened overall course of illness COLLEGE PARK, Ga., May 7, 2025 /PRNewswire/ -- Altesa BioSciences ...

Regeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY announced mixed results from two late-stage studies, AERIFY-1 and AERIFY-2, on itepekimab for the treatment of chronic obstructive pulmonary ...

"2025 was a year that demonstrated Bambusa's execution-first culture," said Dr. Xu. "With multiple clinical programs advancing in parallel, we are entering 2026 positioned to deliver up to 10 clinical ...

Treatment improved patient reported outcomes, reduced viral load, and maintained lung function compared to placebo; Multi-center, international trial slated for 2026 Dr. Brett Giroir, Chief Executive ...

Treatment improved patient reported outcomes, reduced viral load, and maintained lung function compared to placebo; Multi-center, international trial slated for 2026 AMSTERDAM, Sept. 28, 2025 ...